Towards Precision Medicine in Gestational Diabetes: Pathophysiology and Glycemic Patterns in Pregnant Women With Obesity.

de novo lipogenesis fasting hyperglycemia gestational diabetes glycemia hyperglycemia insulin resistance lipid dysfunction lipidomics obesity oral glucose tolerance test pathophysiology precision medicine pregnancy subgroups triglycerides

Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
18 09 2023
Historique:
received: 07 10 2022
medline: 19 9 2023
pubmed: 24 3 2023
entrez: 23 3 2023
Statut: ppublish

Résumé

Precision medicine has revolutionized our understanding of type 1 diabetes and neonatal diabetes but has yet to improve insight into gestational diabetes mellitus (GDM), the most common obstetric complication and strongly linked to obesity. Here we explored if patterns of glycaemia (fasting, 1 hour, 2 hours) during the antenatal oral glucose tolerance test (OGTT), reflect distinct pathophysiological subtypes of GDM as defined by insulin secretion/sensitivity or lipid profiles. 867 pregnant women with obesity (body mass index ≥ 30 kg/m2) from the UPBEAT trial (ISRCTN 89971375) were assessed for GDM at 28 weeks' gestation (75 g oral glucose tolerance test OGTT; World Health Organization criteria). Lipid profiling of the fasting plasma OGTT sample was undertaken using direct infusion mass spectrometry and analyzed by logistic/linear regression, with and without adjustment for confounders. Insulin secretion and sensitivity were characterized by homeostatic model assessment 2b and 2s, respectively. In women who developed GDM (n = 241), patterns of glycaemia were associated with distinct clinical and biochemical characteristics and changes to lipid abundance in the circulation. Severity of glucose derangement, rather than pattern of postload glycaemia, was most strongly related to insulin action and lipid abundance/profile. Unexpectedly, women with isolated postload hyperglycemia had comparable insulin secretion and sensitivity to euglycemic women, potentially indicative of a novel mechanistic pathway. Patterns of glycemia during the OGTT may contribute to a precision approach to GDM as assessed by differences in insulin resistance/secretion. Further research is indicated to determine if isolated postload hyperglycemia reflects a different mechanistic pathway for targeted management.

Identifiants

pubmed: 36950879
pii: 7084352
doi: 10.1210/clinem/dgad168
doi:

Substances chimiques

Blood Glucose 0
Insulin 0
Lipids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2643-2652

Subventions

Organisme : Medical Research Council
ID : MC-UU-12012/4
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-0407-10452
Pays : United Kingdom
Organisme : Diabetes UK
ID : 14/0004849
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : CZB/A/680
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M027252/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L002477/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/4
Pays : United Kingdom
Organisme : Department of Health
ID : SC039280
Pays : United Kingdom
Organisme : Diabetes UK
ID : 17/0005712
Pays : United Kingdom

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Sara L White (SL)

Department of Women and Children's Health, School of Life Course and Population Sciences, Faculty of Life Sciences and Medicine, King's College London, London, SE1 7EH, UK.

Albert Koulman (A)

Core Metabolomics and Lipidomics Laboratory, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke's Treatment Centre, Cambridge, CB2 0QQ, UK.
Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke's Treatment Centre, Cambridge, CB2 0QQ, UK.

Susan E Ozanne (SE)

Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke's Treatment Centre, Cambridge, CB2 0QQ, UK.

Samuel Furse (S)

Core Metabolomics and Lipidomics Laboratory, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke's Treatment Centre, Cambridge, CB2 0QQ, UK.
Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke's Treatment Centre, Cambridge, CB2 0QQ, UK.

Lucilla Poston (L)

Department of Women and Children's Health, School of Life Course and Population Sciences, Faculty of Life Sciences and Medicine, King's College London, London, SE1 7EH, UK.

Claire L Meek (CL)

Core Metabolomics and Lipidomics Laboratory, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke's Treatment Centre, Cambridge, CB2 0QQ, UK.
Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke's Treatment Centre, Cambridge, CB2 0QQ, UK.
Department of Clinical Biochemistry/Wolfson Diabetes & Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH